TAT and neoplasm: In Adult T-cell Leukemia/Lymphoma models driven by the HTLV/Tat oncogene and constitutively expressed NF-kB, serial p65 siRNA systemic dosing fully suppressed tumor growth in the rapid growing tumor cohorts [167].